Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Study sponsor: ACADIA Pharmaceuticals Inc. · ACAD
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-05-05Actual
Enrollment · participants595Actual
Source updated2024-12-20Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.